Sofie

Executive Summary

Sofie is a US-based biotechnology company at the forefront of theranostics, combining molecular diagnostics and targeted radiopharmaceuticals to improve patient outcomes. Founded in 2011 and headquartered in Culver City, California, the company has built an integrated platform that spans proprietary drug development, contract manufacturing, and a network of radiopharmacies. This vertically integrated model allows Sofie to control the entire value chain from discovery to patient dose delivery, positioning it uniquely in the rapidly growing radiopharmaceutical field. The company's pipeline focuses on next-generation targeted radiotherapeutics and diagnostics, with its lead candidate in Phase 3 development for oncology indications. With a robust infrastructure and expertise in radiochemistry, Sofie is well-positioned to capitalize on the increasing demand for precision medicine. The company's contract manufacturing business provides a steady revenue stream while its proprietary pipeline offers upside potential. Key upcoming catalysts include Phase 3 clinical data readouts, regulatory interactions, and potential strategic partnerships. Given the competitive landscape and the technical challenges of radiopharmaceutical production, Sofie's integrated network provides a significant barrier to entry. The company's conviction score reflects its strong positioning in the theranostics space, though execution risk remains as it advances through late-stage development.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 Clinical Trial Data Readout for Lead Theranostic Candidate65% success
• Q2 2027FDA Pre-NDA Meeting or Breakthrough Therapy Designation50% success
• Q3 2026Expansion of Radiopharmacy Network through Acquisition or Partnership70% success